MIRA Pharmaceuticals, Inc. reported preclinical data for Mira-55, a cannabinoid analog in development for chronic inflammatory pain. The data demonstrated Mira-55's differentiated mechanism of action and anxiolytic activity relative to THC, showing no locomotor suppression or catalepsy. MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry and develops cannabinoid-based therapeutic agents.
